NCT01771822已完成1 期
Cumulative Irritancy Patch Test (Cipt) of Ibuprofen 5% Topical Gel in Human Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Assessment of local skin irritation at patch sites
研究概览
简要总结
This study will determine the potential of Ibuprofen 5% Topical Gel and its vehicle gel to cause irritation after repeated topical application to the healthy skin of human subjects under controlled conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and/or female subjects (to be confirmed by medical history) 18 years of age or older, female subjects of childbearing potential and males who are using an acceptable form of birth control, subjects who are free of any systemic or dermatologic disorder
排除标准
- •Have skin disease at the application site, not willing to stop use of systemic or topical analgesics, corticosteroids, or antihistamines, unwilling or unable to stop use of sunscreens, creams, or similar products on the back during the study
研究组 & 干预措施
Ibuprofen 5% topical gel
Experimental
干预措施: Ibuprofen 5% topical gel (Drug)
Topical gel vehicle
Experimental
干预措施: Topical gel vehicle (Drug)
Sodium lauryl sulfate 0.2%
Active Comparator
干预措施: Sodium lauryl sulfate 0.2% (Drug)
Sodium chloride solution 0.9% (saline)
Sham Comparator
干预措施: Sodium chloride solution 0.9% (saline) (Drug)
结局指标
主要结局
Assessment of local skin irritation at patch sites
时间窗: Daily for 21 days, Days 2 through 22
次要结局
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)(Days 1 through 22, + 28 days after last product administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
RIPT of Ibuprofen Topical GelPainNCT01787448Pfizer234
已完成
3 期
Topical Ibuprofen for Delayed Onset Mulscle SorenessPainNCT01794923Pfizer205
Unknown
3 期
Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g GelMuscular AtrophySprainsTendonitisNCT01373697Laboratório Teuto Brasileiro S/A144
已完成
2 期
Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMSPain, AcuteNCT03852459Aponia Laboratories, Inc.251
已完成
不适用
14-Day Cumulative Irritation Patch Test in Subjects With Normal SkinCumulative IrritationNCT02309294Church & Dwight Company, Inc.43